With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

Looking to make money fast? Here are some ways to make $100 or more in a single day to stack cash fast in your savings before ...

A Buffett-inspired strategy focuses on quality businesses bought at fair prices. The post I'd listen to Warren Buffett and buy quality ASX shares at fair prices today appeared first on The Motley Fool ...

Investors showed little affection for our healthcare heavyweights in February, cooling even on solid results. Maybe cheaper ...

Their makers claim they can detect dozens of cancer types — but some scientists say they could be missing many cancers or delivering the wrong diagnosis.

Doctors share everything to know about the buzzy treatment.

Readers argue that house prices will remain unaffordable until the government reduces the tax relief investors receive.

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...

CSL taps ex-vaccine division head Gordon Naylor as interim CEO Appointment of Naylor is a salvage mission, says analyst CSL shares close 5% lower; co to report HY results on Wed Feb 10 (Reuters) - ...

HOUSTON — A 68-year-old Houston woman says she spent more than a year trying to find the source of water flowing into her backyard, only to learn the leak may be coming from a business behind her home ...

Feb 11 (Reuters) - Australia's CSL reported a first‑half profit decline on Wednesday, hit by weaker albumin sales and policy pressures, and moved to expand its share buyback by $250 million in a bid ...

Tests of dozens of baby formulas by Consumer Reports found that nearly half contained potentially dangerous chemicals.